New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymosin Alpha-1 vs Prostamax

Thymosin Alpha-1 vs Prostamax

Side-by-side comparison of key properties, dosing, and research.

Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1
Anti-Aging & Longevity
Prostamax
Summary
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Half-Life
2–3 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.8–1.6 mg
10 mg per day
Frequency
Twice weekly
Daily for 10–30 days
Key Benefits
  • Enhances T-cell and NK cell activity
  • Supports recovery from viral and bacterial infections
  • May reduce inflammation systemically
  • Supports healthy aging and immune resilience
  • Improves vaccine response
  • Supports liver health
  • May help with chronic fatigue syndrome and post-viral conditions
  • Approved in multiple countries for hepatitis B and C treatment
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
Side Effects
  • Injection site irritation
  • Mild flu-like symptoms initially (immune activation)
  • Fatigue (rare)
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
Stacks With